23:09 , May 10, 2019 |  BioCentury  |  Product Development

Exelixis to fuel pipeline growth with Cabometyx cash flows

On the back of the successful launch of Cabometyx cabozantinib, Exelixis is not only using the increased free cash flow to expand the drug’s label, it also thinks it has the firepower to build out...
00:42 , Apr 19, 2019 |  BC Week In Review  |  Clinical News

BMS reports detailed survival data for failed Opdivo maintenance trial in SCLC

Bristol-Myers said Opdivo nivolumab plus Yervoy ipilimumab as maintenance therapy of extensive-stage disease small cell lung cancer following first-line platinum-based chemotherapy led to a median overall survival of 9.2 months vs. 9.6 months for placebo...
13:59 , Apr 9, 2019 |  BC Extra  |  Company News

BeiGene, BioAtla in deal for conditionally activated CTLA-4 inhibitor

BioAtla granted BeiGene a license to BA3071 (CAB-CTLA-4), a conditionally activated inhibitor of CTLA-4, that the partners will develop jointly to treat cancer. The companies plan to test the mAb as monotherapy and in combination...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
00:04 , Apr 6, 2019 |  BioCentury  |  Finance

Everybody up

Biotech stocks were off to a strong start in 1Q19, with 71% of companies tracked by BioCentury seeing market cap growth in the quarter. Across all market cap bands, biotechs saw a median gain of...
23:56 , Apr 4, 2019 |  BC Week In Review  |  Clinical News

Jounce reports detailed data backing tumor-agnostic approach

Jounce reported detailed PFS and OS data at AACR for vopratelimab (JTX-2011) that support a tumor-agnostic approach for the ICOS agonist to select patient populations more likely to respond to the therapy. At the American...
00:15 , Mar 9, 2019 |  BC Extra  |  Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy....
22:14 , Mar 1, 2019 |  BioCentury  |  Product Development

Prostate cancer disrupted

Two imminent disruptions threaten to upend the treatment landscape for prostate cancer, changing who gets anti-androgen therapies and ushering in the first new MOAs in decades. The launch of generic abiraterone means next generation anti-androgens...
23:09 , Feb 26, 2019 |  BC Extra  |  Company News

CytomX R&D day reveals Probody toxicity, chopped BMS deal

CytomX Therapeutics Inc. (NASDAQ:CTMX) lost $6.03 (32%) to $13.13 on Tuesday after reporting severe toxicity signals with its CD166 Probody-drug conjugate, and disclosing that partner Bristol-Myers Squibb Co. (NYSE:BMY) terminated three targets under their discovery...
00:41 , Feb 9, 2019 |  BioCentury  |  Product Development

Genentech takes the wheel

Roche has good cause to call on Genentech to prevent it from losing its long-standing dominance in cancer. While the pharma is late to the party in immuno-oncology, its former biotech unit is behind at...